 |
市場調查報告書
商品編碼
2075252
糖尿病胃麻痺治療市場：依產品類型、適應症、通路和地區分類Diabetic Gastroparesis Treatment Market, By Product Type, By Disease Indication, By Distribution Channel, and By Region |
||||||
預計到 2026 年，糖尿病胃麻痺治療市場規模將達到 25.312 億美元，到 2033 年將達到 32.863 億美元。預計 2026 年至 2033 年的複合年成長率為 3.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 25.312億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 3.80% | 2033年市場規模預測： | 32.863億美元 |
胃排空排放是指在沒有機械性阻塞徵兆的情況下，胃內容物排放延遲的疾病。糖尿病性排放延遲是糖尿病控制不佳時可能出現的併發症，原因是自主神經系統、神經細胞、胃腸道特化起搏細胞、胃腸道平滑肌細胞的協調性和功能受損。糖尿病性胃麻痺是由於自主神經系統和腸神經系統功能障礙所致。慢性高血糖（或葡萄糖攝取效率降低）會導致神經細胞損傷，進而引起肌間神經傳導異常、抑制性神經細胞功能受損、胃平滑肌細胞和節律細胞功能障礙。
這些功能障礙共同作用，導致胃幽門收縮次數減少、幽門與十二指腸收縮排放以及幽門痙攣，最終導致胃排空排放（胃麻痺）。糖尿病患者如果有小腸動力異常，也可能出現胃排空排放，尤其是固態排空延遲。這被認為與胃的機制類似。此外，有些糖尿病患者可能出現胃順應性（自主性）改變，也可能導致排放延遲。
市場動態
全球糖尿病盛行率不斷上升、老年人口成長、久坐生活方式盛行、藥物價格和可及性提高，以及與糖尿病性胃麻痺相關的研發活動，共同推動了全球糖尿病性胃麻痺治療市場的成長。例如，2020年6月23日，美國製藥公司Evoke Pharma宣布，其用於新藥認證成人急性及復發性糖尿病性胃麻痺症狀的鼻噴霧Gimoti已獲得美國食品藥物管理局（FDA）的批准。由於擔心副作用，甲氧氯普胺的使用受到限制。因此，鼻腔給藥此新的給藥途徑應運而生。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數創建了全球糖尿病胃麻痺市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 全球糖尿病胃麻痺治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球糖尿病胃麻痺治療市場中使用的各種策略矩陣，相關人員將能夠做出更順利的決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
第4章 全球糖尿病胃麻痺治療市場：依產品類型分類，2021-2033年
- 製藥
- 外科治療產品
第5章 全球糖尿病胃麻痺治療市場：依疾病適應症分類，2021-2033年
- 補償胃輕癱
- 胃功能障礙
第6章 全球糖尿病胃麻痺治療市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球糖尿病胃麻痺治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情勢
- Janssen Global Services, LLC
- Cardinal Health, Inc.
- Evoke Pharma, Inc.
- Salix Pharmaceuticals, Inc.
- Alfa Wassermann SPA
- Abbott Laboratories
- Medtronic Plc
- CR Bard, Inc.（Becton, Dickinson and Company）
- Rhythm Pharmaceuticals, Inc.
- Boston Scientific Corporation
- Kimberly-Clark Corporation.
- Vanda Pharmaceuticals, Inc.
- Allergan, plc.
第9章
- 調查方法
- 關於本公司
Diabetic Gastroparesis Treatment Market is estimated to be valued at USD 2,531.2 Mn in 2026 and is expected to reach USD 3,286.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,531.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.80% | 2033 Value Projection: | USD 3,286.3 Mn |
Gastroparesis is the delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract. Diabetic gastroparesis occurs as a result of dysfunction in the autonomic and enteric nervous systems. Chronically high levels of blood glucose (or inefficient glucose uptake) lead to neuronal damage resulting in abnormal myenteric neurotransmission, impaired inhibitory neuronal function, and dysfunctional smooth muscle and pacemaker cells of stomach.
Altogether, this dysfunction results in a combination of fewer contractions of the antrum, uncoordinated antro-duodenal contractions, and pyloric spasms, ultimately resulting in delayed gastric emptying (gastroparesis). Delayed gastric emptying in patients with diabetes, particularly of solids, may also occur in the setting of abnormal small bowel motility, which is thought to occur by a similar mechanism as that which is described in the stomach. Some patients with diabetes may additionally experience changes in gastric compliance, both increased or decreased, which may also contribute to delayed gastric emptying.
Market Dynamics
Increasing prevalence of diabetes worldwide, increasing geriatric population and sedentary lifestyle, increasing affordability and accessibility of medication to patients, and research and development activities on diabetic gastroparesis attributed to the growth of global diabetic gastroparesis treatment market. For instance, on June 23, 2020, Evoke Pharma, a U.S.-based pharmaceutical company, announced that the U.S. Food And Drug Administration has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The drug, Metoclopramide has limited use due to associated side effects. Hence, a novel approach by introducing drug in trans nasal pathway is taken.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic gastroparesis market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic gastroparesis treatment market
Detailed Segmentation:
- Global Diabetic Gastroparesis Treatment Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
- Drugs
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
- Global Diabetic Gastroparesis Treatment Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
- Compensated Gastroparesis
- Gastric Failure
- Global Diabetic Gastroparesis Treatment Market, By Distribution channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Diabetic Gastroparesis Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Janssen Global Services
- LLC, Cardinal Health, Inc.
- Evoke Pharma, Inc.
- Salix Pharmaceuticals, Inc.
- Alfa Wassermann SPA
- Abbott Laboratories
- Medtronic Plc.,
- C.R. Bard, Inc. (Becton, Dickinson and Company)
- Rhythm Pharmaceuticals, Inc.
- Boston Scientific Corporation
- Kimberly-Clark Corporation
- Vanda Pharmaceuticals, Inc.
- Allergan, plc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment trends
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
5. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Compensated Gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Gastric Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Global Diabetic Gastroparesis Treatment Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021- 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Janssen Global Services, LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cardinal Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Evoke Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Salix Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alfa Wassermann SPA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Medtronic Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- C.R. Bard, Inc. (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rhythm Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boston Scientific Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kimberly-Clark Corporation.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vanda Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Allergan, plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
糖尿病胃麻痺治療市場規模、佔有率和成長分析：按穩定劑化學性質、PVC材料狀態、終端用戶產業、分銷管道和地區分類－2026-2033年產業預測
糖尿病胃排空排放治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型分類，2021-2031年
2026 年至 2032 年胃輕癱治療市場（按藥物、疾病類型、給藥途徑、最終用戶和地區分類）
胃輕癱治療市場按藥物類別、疾病適應症、類型、給藥途徑、分銷管道和地區分類
糖尿病胃輕癱市場，按類型、治療、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測胃輕癱治療市場，按藥物類別、類型、給藥途徑、疾病適應症、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測